Caribou Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

CRBU$0.41-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-InCapital · Accumulated Other Comprehensive (Loss) Income · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
BALANCE—December 31, 2023	88,448,948	$8	$667,648	$30	$(299,285)	$368,401
Issuances of common stock under ESPP	122,035	—	667	—	—	667
Issuances of common stock on exercises of options	134,347	—	489	—	—	489
Issuances of common stock in connection with our ATM offering, net of offering expenses	1,594,171	1	11,329	—	—	11,330
Issuances of common stock upon vesting of RSUs	15,000	—	—	—	—	—
Stock-based compensation expense	—	—	3,988	—	—	3,988
Net loss	—	—	—	—	(41,234)	(41,234)
Other comprehensive loss	—	—	—	(352)	—	(352)
BALANCE—March 31, 2024	90,314,501	$9	$684,121	$(322)	$(340,519)	$343,289
Issuances of common stock under ESPP	400	—	2	—	—	2
Issuances of common stock on exercises of options	47,870	—	129	—	—	129
Stock-based compensation expense	—	—	4,738	—	—	4,738
Net loss	—	—	—	—	(37,697)	(37,697)
Other comprehensive income	—	—	—	3	—	3
BALANCE—June 30, 2024	90,362,771	$9	688,990	$(319)	$(378,216)	$310,464
Issuances of common stock under ESPP	138,743	—	246	—	—	246
Issuances of common stock upon vesting of RSUs	51,173	—	—	—	—	—
Stock-based compensation expense	—	—	4,069	—	—	4,069
Net loss	—	—	—	—	(34,684)	(34,684)
Other comprehensive income	—	—	—	1,108	—	1,108
BALANCE—September 30, 2024	90,552,687	$9	$693,305	$789	$(412,900)	$281,203
BALANCE—December 31, 2022	61,029,184	$6	$499,598	$(1,518)	$(197,215)	$300,871
Issuances of common stock under ESPP	70,271	—	404	—	—	404
Issuances of common stock on exercises of options	55,433	—	115	—	—	115
Issuances of common stock in connection with our ATM offering, net of offering expenses	168,635	—	1,007	—	—	1,007
Stock-based compensation expense	—	—	3,131	—	—	3,131
Net loss	—	—	—	—	(28,044)	(28,044)
Other comprehensive income	—	—	—	788	—	788
BALANCE—March 31, 2023	61,323,523	$6	$504,255	$(730)	$(225,259)	$278,272
Issuances of common stock on exercises of options	86,085	—	236	—	—	236
Issuances of common stock pursuant to private placement with Pfizer	4,690,431	—	17,290	—	—	17,290
Stock-based compensation expense	—	—	3,585	—	—	3,585
Net loss	—	—	—	—	(29,519)	(29,519)
Other comprehensive loss	—	—	—	(406)	—	(406)
BALANCE—June 30, 2023	66,100,039	$6	$525,366	$(1,136)	$(254,778)	$269,458
Issuances of common stock under ESPP	68,183	—	382	—	—	382
Issuances of common stock on exercises of options	83,407	—	372	—	—	372
Issuances of common stock upon vesting of RSUs	63,596	—	—	—	—	—
Issuances of common stock in connection with follow-on public offering, net of offering expenses	22,115,384	2	134,423	—	—	134,425
Stock-based compensation expense	—	—	3,478	—	—	3,478
Net loss	—	—	—	—	(10,002)	(10,002)
Other comprehensive income	—	—	—	155	—	155
BALANCE—September 30, 2023	88,430,609	$8	$664,021	$(981)	$(264,780)	$398,268

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.